318465-71-3

Usage

Uses

Used in Pharmaceutical Development:
(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-acetic acid is used as a potential therapeutic agent for inhibiting the activity of certain enzymes and receptors in the body. Its ability to target specific pathways makes it a valuable compound for the development of new drugs.
Used in Neuroprotective Applications:
In the field of neuroscience, (6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-acetic acid is used as a neuroprotective agent due to its potential to shield the nervous system from damage or disease. Its protective properties are being investigated for various neurological conditions.
Used in Anti-inflammatory Applications:
(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-acetic acid is also used as an anti-inflammatory agent, leveraging its potential to reduce inflammation in the body. This application is being explored for treating conditions where inflammation plays a significant role in disease progression.
Used in Medicinal Chemistry Research:
In the realm of medicinal chemistry, (6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-acetic acid serves as a subject of study for its chemical structure and potential interactions with biological targets. Its structure may provide insights into the design of new drugs and therapeutics.
Used in Drug Discovery:
(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-acetic acid is utilized in drug discovery processes to identify new molecular targets and develop novel compounds with specific biological activities. Its potential in various applications makes it a valuable asset in the search for new treatments and therapies.

Upstream product

• 1745-07-9 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline 
• 503607-26-9 ethyl 2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)acetate 

Relevant academic research and scientific papers

Engineering Orthogonal Methyltransferases to Create Alternative Bioalkylation Pathways

S-adenosyl-l-methionine (SAM)-dependent methyltransferases (MTs) catalyse the methylation of a vast array of small metabolites and biomacromolecules. Recently, rare carboxymethylation pathways have been discovered, including carboxymethyltransferase enzymes that utilise a carboxy-SAM (cxSAM) cofactor generated from SAM by a cxSAM synthase (CmoA). We show how MT enzymes can utilise cxSAM to catalyse carboxymethylation of tetrahydroisoquinoline (THIQ) and catechol substrates. Site-directed mutagenesis was used to create orthogonal MTs possessing improved catalytic activity and selectivity for cxSAM, with subsequent coupling to CmoA resulting in more efficient and selective carboxymethylation. An enzymatic approach was also developed to generate a previously undescribed co-factor, carboxy-S-adenosyl-l-ethionine (cxSAE), thereby enabling the stereoselective transfer of a chiral 1-carboxyethyl group to the substrate.

Aromatic-ring azacyclo derivatives and application thereof

Aromatic-ring azacyclo derivatives and an application thereof are provided. The invention relates to compounds represented by the formula (V), and a preparation method and an application thereof in medicines. In particular, the invention relates to derivatives of the compounds represented by the general formula (V), and a preparation method and the application thereof as therapeutic agents in prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, type-II diabetes, hyperglycemia, obesity or insulin resistance syndromes and metabolic syndromes. The compounds disclosed by the invention also can reduce total cholesterol, LDL-cholesterol and triglycerides, increase the expression of hepatic LDL receptors and inhibit the expression of PCSK9.

N-heterocyclic derivatives

The present invention relates N-heterocyclic derivatives for treating or preventing neuronal damage associated with neurological diseases. The invention also provides compositions comprising the compounds of the present invention and methods of utilizing those compositions for treating or preventing neuronal damage.